Tirzepatide clinical trials
Also written LY3298176, Mounjaro and Zepbound.
ClinicalTrials.gov finds 317 studies for Tirzepatide. How that becomes 191 here
Every study that search finds has been read, to see whether and how it gives Tirzepatide. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 317Found by its intervention search · See all 317 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 255 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −6
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · Earlier treatment; orforglipron is tested after itReport a problem
- A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)NCT06605703 · Earlier treatment; the study tests what follows stopping itReport a problem
- Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 AgonistsNCT06640972 · Earlier treatment; RDX-002 is tested after stopping itReport a problem
- MAINTAIN (Mucosal AblatIoN Therapy After INcretins)NCT06734312 · Earlier treatment; a procedure is tested after stopping itReport a problem
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900 · Earlier treatment; survodutide is started after itReport a problem
- 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 ReceptorNCT07929233 · Participants already take a GLP-1 drug; fasting before endoscopy is comparedReport a problem
- 311Give Tirzepatide to participants
- −61Observe patients on it, or give it outside a trial
- −21Compare another treatment with it
- −38Give it beside what is tested
- 191Test it: the count on this site
Get an email when these change. Save the Tirzepatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 May 2022 · MOUNJARO · NDA 215866 (FDA, Drugs@FDA)
- European Union
- 15 Sept 2022 · Mounjaro · EMEA/H/C/005620 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
187 studies that test it; most in 2026 (67); 4 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 13 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 15 |
| 2024 | 19 |
| 2025 | 45 |
| 2026 | 67 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 72 · Other 119
Eli Lilly and Company (69) · The Cleveland Clinic (4) · Mayo Clinic (4) · University of Texas Southwestern Medical Center (3) · University Medical Centre Ljubljana (3) · Stanford University (3) · Shahid Beheshti University of Medical Sciences (3) · Zagazig University (2)
Often tested with
Tested in the same studies.
Semaglutide (23) · Bimagrumab (3) · Dulaglutide (2) · Pioglitazone (2) · Bupropion hydrochloride, naltrexone hydrochoride drug combination (1) · Phentermine (1) · Topiramate (1) · Dual GIP/GLP-1 Receptor Agonist (1)
Related medicines
As reviewed, each with the page that says it.
- One of GLP-1 receptor agonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Tirzepatide is the comparator. A study of two new drugs counts under both.
- 1Retatrutide · Eli Lilly and Company · next primary completion Nov 2026
- 1Enicepatide · Hoffmann-La Roche · next primary completion Apr 2029
- 1Berobenatide · Pfizer · next primary completion Feb 2028
New treatments tested with it · 8 most studied
New when their studies opened, with Tirzepatide beside them; studies of each.
Reaching primary completion within a year · 47, 6 in phase 3
Studies that test Tirzepatide, phase 3 first.
- Nov 2026A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightPhase 3 · Eli Lilly and Company
- Nov 2026A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightPhase 3 · Eli Lilly and Company
- Feb 2027Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Phase 3 · Hudson Biotech
- Jun 2027Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With ObesityPhase 3 · Shahid Beheshti University of Medical Sciences
- Oct 2027A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPhase 3 · Eli Lilly and Company
- Oct 2027A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)Phase 3 · Eli Lilly and Company
- Nov 2026A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusPhase 1 · Eli Lilly and Company
- Nov 2026Tirzepatide Impact Assessment StudyNot applicable · Texas Tech University
- Dec 2026The Long COVID Treatment TrialPhase 2 · Scripps Translational Science Institute
- Dec 2026A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityPhase 1 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses Tirzepatide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 191
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)RecruitingPhase 3Hudson BiotechNCT07481747Tirzepatide against placebo on weightWritten as TirzepatideReport a problem
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialRecruitingPhase 2/3yifang zhuNCT07734792Tirzepatide added to thrombectomy in acute strokeWritten as TirzepatideReport a problem
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingPhase 3Eli Lilly and CompanyNCT06937086Added to mirikizumab in ulcerative colitis with obesityWritten as TirzepatideReport a problem
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)RecruitingPhase 4Eli Lilly and CompanyNCT06857942Added to ixekizumab in plaque psoriasisWritten as TirzepatideReport a problem
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT06937099Added to mirikizumab in Crohn's disease with obesityWritten as TirzepatideReport a problem
- Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)RecruitingPhase 3Eli Lilly and CompanyNCT07817875Tirzepatide against placebo in children 6 to 11Written as TirzepatideReport a problem
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNot yet recruitingPhase 4Jing LuoNCT07832084Tapering against maintenance or other medicinesReport a problem
- Tirzepatide for Treatment of CCCARecruitingPhase 2Johns Hopkins UniversityNCT07734870Single-arm tirzepatide in scarring hair lossWritten as TirzepatideReport a problem
- Tirzepatide and Organ-specific Biological AgingEnrolling by invitationPhase 2Atria Research and Global Health Institute (ARGHI)NCT07906041Tirzepatide against usual care on brain ageing markersWritten as TirzepatideReport a problem
- Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep ApnoeaNot yet recruitingPhase 2/3Woolcock Institute of Medical ResearchNCT07846865Tirzepatide against CPAP in sleep apneaWritten as TirzepatideReport a problem
- Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic PatientsNot yet recruitingNot applicableAkhtar Saeed Medical and Dental CollegeNCT07728318Added to oral diabetes drugs against those aloneReport a problem
- Impact of GLP-1 Receptor Agonist Therapy on Alcohol PharmacokineticsNot yet recruitingPhase 1University of Wisconsin, MadisonNCT07758231Its effect on how the body handles alcoholReport a problem
- Mechanisms of Weight Loss: Tirzepatide vs SemaglutideRecruitingPhase 4McMaster UniversityNCT07900074Tirzepatide against semaglutide on energy balanceWritten as TirzepatideReport a problem
- Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibRecruitingPhase 1University of ChicagoNCT07782359For weight gain on lorlatinibWritten as TirzepatideReport a problem
- Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With ObesityNot yet recruitingPhase 4Mayo ClinicNCT07893457One dose against placebo on acid refluxWritten as TirzepatideReport a problem
- Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderRecruitingPhase 2University of Texas Southwestern Medical CenterNCT07825857Tirzepatide against placebo in methamphetamine use disorderWritten as TirzepatideReport a problem
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruitingPhase 2University of FloridaNCT07107334GLP-1 drug with an LNG-IUD, tirzepatide an optionReport a problem
- Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityRecruitingNot applicableDasman Diabetes InstituteNCT07574723Flexible titration against the label'sWritten as Tirzepatide (Per-label titration)Report a problem
- PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT07874828Feasibility in young sarcoma survivorsWritten as TirzepatideReport a problem
- Dietary, Medication, and Endoscopic Interventions for Post-Bariatric HypoglycemiaNot yet recruitingNot applicableStanford UniversityNCT07878494GLP-1 therapy for post-bariatric hypoglycaemiaReport a problem
See all 191 studies that test Tirzepatide →
Behind its US label · 12 — the studies the FDA label of MOUNJARO, ZEPBOUND describes
From the Clinical Studies section of MOUNJARO (2026-08), ZEPBOUND (2026-08), as openFDA has it. A study the site does not hold is left out.
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskCompletedPhase 3Eli Lilly and CompanyNCT03730662Report a problem
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT03882970Report a problem
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneCompletedPhase 3Eli Lilly and CompanyNCT03954834Report a problem
- A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT03987919Report a problem
- A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without MetforminCompletedPhase 3Eli Lilly and CompanyNCT04039503Report a problem
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT04255433Report a problem
- A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or BothCompletedPhase 3Eli Lilly and CompanyNCT05260021Report a problem
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT04184622Report a problem
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightCompletedPhase 3Eli Lilly and CompanyNCT04657003Report a problem
- A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramCompletedPhase 3Eli Lilly and CompanyNCT04657016Report a problem
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight LossCompletedPhase 3Eli Lilly and CompanyNCT04660643Report a problem
- Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaCompletedPhase 3Eli Lilly and CompanyNCT05412004Report a problem
Tested on its own · 147 — no other medicine in its arm
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)RecruitingPhase 3Hudson BiotechNCT07481747Tirzepatide against placebo on weightWritten as TirzepatideReport a problem
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialRecruitingPhase 2/3yifang zhuNCT07734792Tirzepatide added to thrombectomy in acute strokeWritten as TirzepatideReport a problem
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)RecruitingPhase 4Eli Lilly and CompanyNCT06857942Added to ixekizumab in plaque psoriasisWritten as TirzepatideReport a problem
- Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)RecruitingPhase 3Eli Lilly and CompanyNCT07817875Tirzepatide against placebo in children 6 to 11Written as TirzepatideReport a problem
- Tirzepatide for Treatment of CCCARecruitingPhase 2Johns Hopkins UniversityNCT07734870Single-arm tirzepatide in scarring hair lossWritten as TirzepatideReport a problem
- Tirzepatide and Organ-specific Biological AgingEnrolling by invitationPhase 2Atria Research and Global Health Institute (ARGHI)NCT07906041Tirzepatide against usual care on brain ageing markersWritten as TirzepatideReport a problem
- Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep ApnoeaNot yet recruitingPhase 2/3Woolcock Institute of Medical ResearchNCT07846865Tirzepatide against CPAP in sleep apneaWritten as TirzepatideReport a problem
- Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic PatientsNot yet recruitingNot applicableAkhtar Saeed Medical and Dental CollegeNCT07728318Added to oral diabetes drugs against those aloneReport a problem
- Impact of GLP-1 Receptor Agonist Therapy on Alcohol PharmacokineticsNot yet recruitingPhase 1University of Wisconsin, MadisonNCT07758231Its effect on how the body handles alcoholReport a problem
- Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibRecruitingPhase 1University of ChicagoNCT07782359For weight gain on lorlatinibWritten as TirzepatideReport a problem
- Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With ObesityNot yet recruitingPhase 4Mayo ClinicNCT07893457One dose against placebo on acid refluxWritten as TirzepatideReport a problem
- Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderRecruitingPhase 2University of Texas Southwestern Medical CenterNCT07825857Tirzepatide against placebo in methamphetamine use disorderWritten as TirzepatideReport a problem
- Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityRecruitingNot applicableDasman Diabetes InstituteNCT07574723Flexible titration against the label'sWritten as Tirzepatide (Per-label titration)Report a problem
- PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT07874828Feasibility in young sarcoma survivorsWritten as TirzepatideReport a problem
- Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)RecruitingPhase 1National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT07559500Tirzepatide against placebo on dopamine in alcohol use disorderWritten as TirzepatideReport a problem
- Tirzepatide for the Treatment of Cannabis Use DisorderNot yet recruitingPhase 2Brigham and Women's HospitalNCT07265752One dose against placebo on cannabis cue cravingWritten as TirzepatideReport a problem
- Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative StudyRecruitingNot applicableNational Medical Research Center for Therapy and Preventive MedicineNCT07866183Tirzepatide against vagus nerve stimulation in obesityWritten as TirzepatideReport a problem
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityRecruitingPhase 4Mayo ClinicNCT07218445Tirzepatide against placebo on menopausal hot flushesWritten as TirzepatideReport a problem
- Tirzepatide in Obesity-Driven Endometrial CancerRecruitingEarly Phase 1UNC Lineberger Comprehensive Cancer CenterNCT07065552Pre-operative window study in endometrial cancerWritten as TirzepatideReport a problem
- Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNot yet recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07078838Before surgery in early endometrial cancer, against noneWritten as TirzepatideReport a problem
Showing 20 of 147. See all 147 →
Tested with established drugs · 8 — they are given beside it
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingPhase 3Eli Lilly and CompanyNCT06937086Added to mirikizumab in ulcerative colitis with obesityWritten as TirzepatideReport a problem
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT06937099Added to mirikizumab in Crohn's disease with obesityWritten as TirzepatideReport a problem
- Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)Not yet recruitingPhase 4University of North Carolina, Chapel HillNCT07756359Tirzepatide against anti-diarrhoeal care after pouch surgeryWritten as TirzepatideReport a problem
- Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024RecruitingPhase 2University of MichiganNCT07091734Tirzepatide against usual care in partial lipodystrophyWritten as TirzepatideReport a problem
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06588283Added to ixekizumab in psoriasis with obesityWritten as TirzepatideReport a problem
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06588296Added to ixekizumab in psoriatic arthritis with obesityWritten as TirzepatideReport a problem
- Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 DrugsActive, not recruitingNot applicableNazarbayev UniversityNCT07303556Tirzepatide in heart failure with preserved ejection fractionWritten as Tirzepatide (Mounjaro)Report a problem
- A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT03861039Long-term safety added to oral diabetes medicinesWritten as TirzepatideReport a problem
Tested in a combination · 36 — another drug in the study is under test too
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNot yet recruitingPhase 4Jing LuoNCT07832084Tapering against maintenance or other medicinesReport a problem
- Mechanisms of Weight Loss: Tirzepatide vs SemaglutideRecruitingPhase 4McMaster UniversityNCT07900074Tirzepatide against semaglutide on energy balanceWritten as TirzepatideReport a problem
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruitingPhase 2University of FloridaNCT07107334GLP-1 drug with an LNG-IUD, tirzepatide an optionReport a problem
- Dietary, Medication, and Endoscopic Interventions for Post-Bariatric HypoglycemiaNot yet recruitingNot applicableStanford UniversityNCT07878494GLP-1 therapy for post-bariatric hypoglycaemiaReport a problem
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07165028Tirzepatide against placebo on liver outcomes in MASLDWritten as TirzepatideReport a problem
- Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo TransferNot yet recruitingNot applicableRenJi HospitalNCT07811895Tirzepatide before frozen embryo transferReport a problem
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialRecruitingPhase 2City of Hope Medical CenterNCT07202247An option of GLP-1 treatment against a healthy diet in prostate cancerWritten as TirzepatideReport a problem
- Tirzepatide Impact Assessment StudyRecruitingNot applicableTexas Tech UniversityNCT07740291GLP-1 therapy against lifestyle, tirzepatide an optionReport a problem
- Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenEnrolling by invitationPhase 4Mayo ClinicNCT07057310Semaglutide or tirzepatide with lifestyle in postmenopausal womenReport a problem
- Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in AdolescentsRecruitingPhase 1University of Colorado, DenverNCT06575738Semaglutide or tirzepatide added after bariatric surgeryReport a problem
- Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialNot yet recruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT07676331Window study alone and with letrozole in breast cancerWritten as TirzepatideReport a problem
- New Triple Combination Therapy in Newly Diagnosed Type 2 DiabetesNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07635953In a triple combination against standard therapyReport a problem
- GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityRecruitingNot applicableChina-Japan Friendship HospitalNCT07633639One of three drugs added after sleeve gastrectomyReport a problem
- Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTsRecruitingNot applicableTri-Service General Hospital (TSGH)NCT07589322Tirzepatide and semaglutide head to headReport a problem
- Combination of Biologic and Anti-obesity Therapies in Psoriatic ArthritisRecruitingNot applicableNHS Greater Glasgow and ClydeNCT07443956Tirzepatide, ixekizumab and both on tissue changes in psoriatic arthritisWritten as TirzepatideReport a problem
- Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideRecruitingPhase 4Stanford UniversityNCT06657209Crossover of tirzepatide and pioglitazone in normal-weight diabetesWritten as TirzepatideReport a problem
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityRecruitingPhase 2Massachusetts General HospitalNCT05933499Tirzepatide and new bimagrumab, alone and togetherWritten as TirzepatideReport a problem
- DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNot yet recruitingPhase 4Cambridge University Hospitals NHS Foundation TrustNCT07483801Semaglutide and tirzepatide on blood flowWritten as TirzepatideReport a problem
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesRecruitingPhase 3The University of Texas Health Science Center at San AntonioNCT06246799Tirzepatide with pioglitazone against metformin with sitagliptinWritten as TirzepatideReport a problem
- Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart DiseaseNot yet recruitingPhase 4University Medical Centre LjubljanaNCT07354880Tirzepatide against placebo in congenital heart diseaseReport a problem
Showing 20 of 36. See all 36 →
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests
Tested with Tirzepatide: bremelanotide 1
Beside a new treatment under test · 24 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Tirzepatide: eloralintide 7 · emugrobart 1 · TLC-6740 1 · mibavademab 1 · apitegromab 1 · bimagrumab 1 · nisotirostide 1 · LAE102 1
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07881458In every armPartner in EloraTZP, also given alone for comparisonWritten as eloralintide and tirzepatideReport a problem
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNot yet recruitingPhase 3Eli Lilly and CompanyNCT07881432Partner in EloraTZP, also given alone for comparisonWritten as eloralintide and tirzepatideReport a problem
- A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or ObesityRecruitingPhase 1/2Wave Life Sciences USA, Inc.NCT06842186Partner of new WVE-007Report a problem
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07868354In every armWhat people switch from to new zenagamtideWritten as TirzepatideReport a problem
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Partner of a new drug in one part of a master protocolWritten as TirzepatideReport a problem
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDRecruitingPhase 2Regeneron PharmaceuticalsNCT07527910An option given with new ALN-PNPWritten as TirzepatideReport a problem
- Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor AgonistsRecruitingNot applicableThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07619989Everyone stays on it; vagus nerve stimulation is testedReport a problem
- A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusRecruitingPhase 1/2Arrowhead PharmaceuticalsNCT06937203Partner of new ARO-ALK7Report a problem
- A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese ParticipantsNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07671391Partner of new LAE102 in one entryWritten as LAE102 +TirzepatideReport a problem
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or ObeseNot yet recruitingPhase 2Biomed Industries, Inc.NCT06732245Partner of new NA-931, also given aloneWritten as TirzepatideReport a problem
- Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and ObesityRecruitingPhase 1/2Ikaria Bioscience Pty LtdNCT07245771Partner of new RN3161Written as TirzepatideReport a problem
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusActive, not recruitingPhase 1/2Arrowhead PharmaceuticalsNCT06700538Partner of new ARO-INHBEWritten as TirzepatideReport a problem
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT06603571Partner of new eloralintide, also given aloneWritten as TirzepatideReport a problem
- A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityActive, not recruitingPhase 2Hoffmann-La RocheNCT06965413In every armBackground therapy for new emugrobartWritten as TirzepatideReport a problem
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without DiabetesActive, not recruitingPhase 1OrsoBio, IncNCT05822544Partner of the new drug TLC-6740Written as TirzepatideReport a problem
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityCompletedPhase 2Eli Lilly and CompanyNCT06373146In every armPartner of new mibavademabWritten as TirzepatideReport a problem
- Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on TirzepatideActive, not recruitingNot applicableFractyl Health Inc.NCT06484114Run-in weight loss drug, stopped before Revita is testedReport a problem
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityCompletedPhase 1Eli Lilly and CompanyNCT06916065Partner of new eloralintide in one entryWritten as Eloralintide and TirzepatideReport a problem
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseCompletedPhase 2Scholar Rock, Inc.NCT06445075In every armAn incretin drug new apitegromab is added toWritten as TirzepatideReport a problem
- A Study of LY3841136 in Japanese Participants With Obesity or OverweightCompletedPhase 1Eli Lilly and CompanyNCT06297616Partner of new eloralintide, also given aloneWritten as TirzepatideReport a problem
Showing 20 of 24. See all 24 →
Beside supportive care · 7 — a supportive treatment or test is studied
- Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 DiabetesNot yet recruitingNot applicableGerman Diabetes CenterNCT07926152In every armContinued in both arms; exercise and protein are testedReport a problem
- Resistance Training to Prevent Muscle Loss During Treatment With TirzepatideRecruitingPhase 4Technical University of MunichNCT07777575Everyone takes it; resistance training is testedReport a problem
- High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)Not yet recruitingNot applicableNYU Langone HealthNCT07700030Diet and resistance training are tested in adults prescribed itReport a problem
- Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese IndividualsNot yet recruitingNot applicableAcibadem UniversityNCT07609160Prescribed to everyone; resistance exercise is testedReport a problem
- The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)Not yet recruitingPhase 3University of VirginiaNCT07298915In every armEveryone takes it; exercise is what is testedWritten as TirzepatideReport a problem
- Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA TreatmentRecruitingNot applicableUniversity of ExeterNCT07457437Prescribed to everyone; resistance exercise is testedReport a problem
- Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight LossActive, not recruitingNot applicableSofwave Medical LTDNCT07685834Skin treatment is tested in adults starting itReport a problem
Given beside what is tested · 6 — usual care or a partner of the new treatment
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideRecruitingPhase 2Eli Lilly and CompanyNCT06897475New LY3457263 is added to stable tirzepatideReport a problem
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA TreatmentRecruitingNot applicableHospices Civils de LyonNCT07213323In every armProbiotics are tested in people starting GLP-1 drugsReport a problem
- Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity PharmacotherapyNot yet recruitingNot applicablePhenomix SciencesNCT07728812One option of test-guided obesity treatmentReport a problem
- LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide TherapyRecruitingNot applicableDasman Diabetes InstituteNCT06885736Exercise and protein are tested in patients on itReport a problem
- Tailored Exercise Training Study Among Adults With HFpEFRecruitingPhase 2/3University of Texas Southwestern Medical CenterNCT07223242Exercise is tested, with weight-loss medicines among its armsReport a problem
- Study That Tests AD109 in Patients Taking GLP-1 DrugsCompletedPhase 2ApnimedNCT06400615AD109 is tested in patients on GLP-1 drugsReport a problem
As the comparator · 21 — what is tested is compared with Tirzepatide
- A Study to Evaluate ALN-2232 in Participants With ObesityRecruitingPhase 1/2Alnylam PharmaceuticalsNCT07463846The comparator for new ALN-2232Written as TirzepatideReport a problem
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityRecruitingPhase 3PfizerNCT07845500Staying on it is the comparator for new berobenatideWritten as TirzepatideReport a problem
- AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 DiabetesRecruitingPhase 4The First Affiliated Hospital of Anhui Medical UniversityNCT07697391The comparator for an AI lifestyle programmeWritten as TirzepatideReport a problem
- A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsNot yet recruitingPhase 3Hoffmann-La RocheNCT07889648The comparator for new enicepatideWritten as TirzepatideReport a problem
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver DiseaseRecruitingPhase 4The Cleveland ClinicNCT07058155TIPS with surgery against medical care, tirzepatide an optionReport a problem
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightRecruitingPhase 1Ascletis Pharma (China) Co., LimitedNCT07842640The comparator in new ASC35's dose studyWritten as TirzepatideReport a problem
- A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or MetforminNot yet recruitingPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT07796477The comparator for new SYH2069Written as Tirzepatide Injection 15mgReport a problem
- Fibrosis Lessens After Metabolic SurgeryRecruitingPhase 4The Cleveland ClinicNCT06374875Metabolic surgery against incretin therapy, tirzepatide an optionReport a problem
- AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)Not yet recruitingPhase 4Huazhong University of Science and TechnologyNCT07555730Continuing it is the comparator for an AI lifestyle programmeWritten as TirzepatideReport a problem
- Metabolic Surgery for Atrial Fibrillation EliminationNot yet recruitingPhase 4Ali AminianNCT07027969Metabolic surgery against medical care, tirzepatide an optionReport a problem
- Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesRecruitingPhase 2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07521631The comparator for new HDM1005Written as TirzepatideReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorCompletedPhase 3Novo Nordisk A/SNCT06221969The comparator for CagriSemaWritten as TirzepatideReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothCompletedPhase 3Novo Nordisk A/SNCT06534411The comparator for CagriSemaWritten as TirzepatideReport a problem
- A Study of BGM0504 in Participants With ObesityCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06911203The comparator for new BGM0504Written as TirzepatideReport a problem
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesCompletedPhase 2Novo Nordisk A/SNCT06326047The comparator for new NNC0519-0130Report a problem
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06662383The comparator for new retatrutideWritten as TirzepatideReport a problem
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedPhase 2Gan and Lee Pharmaceuticals, USANCT06737042The comparator for new GZR18Written as TirzepatideReport a problem
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightCompletedPhase 2Novo Nordisk A/SNCT06326060The comparator for new NNC0519-0130Written as TirzepatideReport a problem
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightCompletedPhase 3Novo Nordisk A/SNCT06131437The comparator for CagriSemaWritten as TirzepatideReport a problem
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityActive, not recruitingPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT07000955The comparator for new mazdutide 15 mgWritten as TirzepatideReport a problem
Showing 20 of 21. See all 21 →
Observed · 61 — patients on it are followed, or it is given outside a trial
- GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort StudyRecruitingNoom Inc.NCT07588984Observes compounded tirzepatide with a digital programmeWritten as TirzepatideReport a problem
- Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in ObesityNot yet recruitingTechnical University of MunichNCT07931196Written as TirzepatideReport a problem
- Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With ObesityNot yet recruitingTechnical University of MunichNCT07931235Written as TirzepatideReport a problem
- Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight LossNot yet recruitingTechnical University of MunichNCT07929571Written as TirzepatideReport a problem
- Ocular Changes in Patients Using Tirzepatide or SemaglutideRecruitingIstanbul UniversityNCT07924618Written as TirzepatideReport a problem
- Changes in Body Composition Following Pharmacological Treatment for Obesity.Enrolling by invitationHospital San Carlos, MadridNCT07908940Body composition after weight loss on tirzepatideReport a problem
- Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 DiabetesNot yet recruitingUniversiti Sains MalaysiaNCT07809568Real-world tirzepatide in PakistanReport a problem
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyNot yet recruitingNovartis PharmaceuticalsNCT07881783Observes secukinumab with concurrent GLP-1 drugsReport a problem
- Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese PatientsNot yet recruitingNanjing First Hospital, Nanjing Medical UniversityNCT07847515Observes gut microbiota on tirzepatide and after stoppingWritten as TirzepatideReport a problem
- GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesRecruitingIstanbul Saglik Bilimleri UniversityNCT07858864Observes sarcopenia in GLP-1 usersReport a problem
- Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)Not yet recruitingDr. Md. Alimur RezaNCT07099742Observes tirzepatide against lifestyle in BangladeshWritten as TirzepatideReport a problem
- NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudyNot yet recruitingIstanbul Saglik Bilimleri UniversityNCT07846956Observes optic neuropathy in GLP-1 usersReport a problem
- Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 DiabetesRecruitingInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranNCT07835360Observes body composition after starting GLP-1 drugsReport a problem
- Genetic, Microbiological and Behavioral Factors in ObesityRecruitingJan Kochanowski UniversityNCT07650149Observes what predicts response to tirzepatideReport a problem
- Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass SurgeryNot yet recruitingMario Musella MDNCT07622992Observes it against ketogenic diet before gastric bypassReport a problem
- GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNot yet recruitingMiedziowe Centrum Zdrowia SANCT07787936Observes patients on GLP-1 drugs in heart failureReport a problem
- Comparing Facial Aging Between Identical Twins With 3D ImagingNot yet recruitingPonsky Facial Aesthetics And Plastic Surgery, LlcNCT07760532Observes facial ageing in twins, some on GLP-1 drugsReport a problem
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruitingOhio State UniversityNCT07702461Survey of people on GLP-1 drugsReport a problem
- Salivary Function and Dental Changes During GLP-1 TherapyNot yet recruitingBilecik Seyh Edebali UniversitesiNCT07720466Observes saliva in patients on semaglutide or tirzepatideReport a problem
- Effects of GLP-1 RAs on Human Lactation OutcomesRecruitingUniversity of Colorado, DenverNCT07720414Observes lactation in mothers on GLP-1 drugsReport a problem
Showing 20 of 61. See all 61 →
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting4
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNov 12, 2026NCT07734792
- Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibOct 27, 2026NCT07782359
- Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderOct 26, 2026NCT07825857
- PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility StudyOct 20, 2026NCT07874828
Results posted1
Newly registered3
- Tirzepatide and Organ-specific Biological AgingOct 30, 2026NCT07906041
- Mechanisms of Weight Loss: Tirzepatide vs SemaglutideOct 28, 2026NCT07900074
- Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With ObesityOct 26, 2026NCT07893457
Codes
What other systems call Tirzepatide · ClinicalTrials.gg INT006887
- MeSH (NLM) D000098860TirzepatideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) OYN3CCI6QETIRZEPATIDEConfirmed FDA, NLM, Wikidata
- RxNorm 2601723One source FDA
- Wikidata Q108324770tirzepatideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174817TirzepatideConfirmed FDA, Wikidata
- DrugBank DB15171One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000098860 | Tirzepatide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | OYN3CCI6QE | TIRZEPATIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2601723 | — | One source FDA |
| Wikidata | Q108324770 | tirzepatide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174817 | Tirzepatide | Confirmed FDA, Wikidata |
| DrugBank | DB15171 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.